GILD

#86
Gilead Sciences, Inc. - Common Stock
134.4 3 USD
-0.85%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
134.41
134.48
Range Annuel
104.46
157.27
Changement quotidien
-0.85%
Changement Mensuel
+5.06%
Evolution sur 6 mois
+6.95%
Changement Annuel
+20.44%
Clôture Précédente
135.5 8
Open
134.4 8
Low
134.4 1
High
134.4 8
Volume
640
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 166.9 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry Fabricants de Médicaments — Généralités
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
18.96
ratio cours/chiffre d'affaires
5.88
Dividende par action
0.82
Rendement du dividende (%)
3.99

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

Nouvelles